The New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 8, pp. 709 - 718
Patients with venous thromboembolism who had received initial anticoagulant therapy were studied in two trials of dabigatran. Dabigatran was effective in...
LONG-TERM | 1ST EPISODE | MEDICINE, GENERAL & INTERNAL | MOLECULAR-WEIGHT HEPARIN | PULMONARY-EMBOLISM | PREVENTION | INITIAL TREATMENT | RANDOMIZED-TRIAL | ORAL ANTICOAGULANT-THERAPY | UNFRACTIONATED HEPARIN | ATRIAL-FIBRILLATION | Recurrence | Venous Thromboembolism - mortality | Follow-Up Studies | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Young Adult | Aged, 80 and over | Adult | Female | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | beta-Alanine - adverse effects | beta-Alanine - therapeutic use | International Normalized Ratio | Adolescent | Intention to Treat Analysis | Aged | Hemorrhage - chemically induced | Anticoagulants | Warfarin | Heart attacks | Laboratories | Embolisms | Clinical trials | Scandals | Patients | Thrombosis | Bleeding | Studies | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug dosages | Benzimidazoles | Hemorrhage | Life Sciences | Venous Thromboembolism | beta-Alanine
LONG-TERM | 1ST EPISODE | MEDICINE, GENERAL & INTERNAL | MOLECULAR-WEIGHT HEPARIN | PULMONARY-EMBOLISM | PREVENTION | INITIAL TREATMENT | RANDOMIZED-TRIAL | ORAL ANTICOAGULANT-THERAPY | UNFRACTIONATED HEPARIN | ATRIAL-FIBRILLATION | Recurrence | Venous Thromboembolism - mortality | Follow-Up Studies | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Young Adult | Aged, 80 and over | Adult | Female | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | beta-Alanine - adverse effects | beta-Alanine - therapeutic use | International Normalized Ratio | Adolescent | Intention to Treat Analysis | Aged | Hemorrhage - chemically induced | Anticoagulants | Warfarin | Heart attacks | Laboratories | Embolisms | Clinical trials | Scandals | Patients | Thrombosis | Bleeding | Studies | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug dosages | Benzimidazoles | Hemorrhage | Life Sciences | Venous Thromboembolism | beta-Alanine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 8, p. 709
The study aims to evaluate and compare the efficacy of dabigratan as against warfarin or placebo as a form of treatment for patients with venous...
Drugs | Dose-response relationship (Biochemistry) | Usage | Warfarin | Patient outcomes | Dabigatran etexilate | Dosage and administration | Venous thrombosis | Product/Service Evaluations | Drug therapy | Comparative analysis
Drugs | Dose-response relationship (Biochemistry) | Usage | Warfarin | Patient outcomes | Dabigatran etexilate | Dosage and administration | Venous thrombosis | Product/Service Evaluations | Drug therapy | Comparative analysis
Journal Article
Survey of Anesthesiology, ISSN 0039-6206, 10/2013, Volume 57, Issue 5, pp. 264 - 265
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.